VESCO-R®: Peripheral Blood Derived Mesenchymal Stem Cell Therapy in Regenerative Medicine

Cell therapies offer the opportunity to treat and cure serious unmet medical needs. BioDivide has discovered

an innovative manufacturing technology to develop VESCO-R® - a suspension of autologous Mesenchymal Stem

Cells (MSCs) derived from a limited peripheral blood sample. Current state-of-the-art processes to isolate MSCs

from peripheral blood are highly inefficient and variable. The Company screened >500 conditions to develop

the underpinning science for this break-through technology. Current autologous stem cell biopsy techniques

require invasive surgical procedures (e.g. bone marrow and adipose tissue harvesting under general

anaesthetic). Peripheral blood donation is minimally invasive and would overcome significant barriers to the

industry. BioDivide, in collaboration with Genesis, is seeking Innovate UK Funding to enable the translation of

this technology from the bench to a market-ready manufacturing process and the therapeutic product, VESCO-

R®. BioDivide envisions transforming regenerative medicine by initially validating VESCO-R® for musculoskeletal

disorders in veterinary medicine with the ultimate aim to translate this technology to human health.blic Project Summary